Neil T. Thompson

2.6k citations

47 papers · 1.6k indexed · h-index 24

Co-authors: John F. Lyons L.G. Garland Robert W. Bonser Michael C. Scrutton Nicola G. Wallis Michael Wadsworth M. J. Jarvis Marcus Richards
Topics: Chronic Lymphocytic Leukemia Research (5 papers)PI3K/AKT/mTOR signaling in cancer (5 papers)Cancer-related Molecular Pathways (5 papers)
Cited by: Cell Biology Molecular Biology Oncology
Journals: Nature Communications Blood Cancer Research
Partner nations: United Kingdom United States Japan

In The Last Decade

Neil T. Thompson

46 papers receiving 1.5k citations

Peers

Countries citing papers authored by Neil T. Thompson

Since Specialization

Citations

This map shows the geographic impact of Neil T. Thompson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Neil T. Thompson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Neil T. Thompson more than expected).

Fields of papers citing papers by Neil T. Thompson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Neil T. Thompson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Neil T. Thompson. The network helps show where Neil T. Thompson may publish in the future.

Co-authorship network of co-authors of Neil T. Thompson

This figure shows the co-authorship network connecting the top 25 collaborators of Neil T. Thompson. A scholar is included among the top collaborators of Neil T. Thompson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Neil T. Thompson. Neil T. Thompson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	An experimentally validated approach to automated biological evidence generation in drug discovery using knowledge graphs 2024 ·Nature Communications ·(unknown),Buğra Özer,(unknown),Wayne Chadwick,Daniel J. O’Donovan,(unknown),(unknown),Neil T. Thompson,Ian Roberts	3
2	Computational drug discovery approaches identify mebendazole as a candidate treatment for autosomal dominant polycystic kidney disease 2024 ·Frontiers in Pharmacology ·Philip W. Brownjohn,Azedine Zoufir,Daniel J. O’Donovan,(unknown),(unknown),(unknown),John R. Porter,(unknown),(unknown),Neil T. Thompson	2
3	A novel combination treatment for fragile X syndrome predicted using computational methods 2023 ·Brain Communications ·Wayne Chadwick,(unknown),Patricia Cogram,(unknown),Daniel J. Mason,David T. Brown,Ian Roberts,Daniel J. O’Donovan,Michael R. Tranfaglia,Tim Guilliams,Neil T. Thompson	2
4	ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth 2018 ·Molecular Cancer Therapeutics ·George A. Ward,Edward J. Lewis,Jong Sook Ahn,Christopher N. Johnson,John F. Lyons,(unknown),Joanne M. Munck,Sharna J. Rich,Tomoko Smyth,Neil T. Thompson,Pamela A. Williams,Nicola E. Wilsher,Nicola G. Wallis,Gianni Chessari	53
5	Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib 2016 ·British Journal of Cancer ·Aurélie Courtin,Tomoko Smyth,Keisha Hearn,Harpreet K. Saini,Neil T. Thompson,John F. Lyons,Nicola G. Wallis	23
6	The HSP90 Inhibitor, AT13387, Is Effective against Imatinib-Sensitive and -Resistant Gastrointestinal Stromal Tumor Models 2012 ·Molecular Cancer Therapeutics ·Tomoko Smyth,Thomas Van Looy,Jayne Curry,Ana M. Rodrı́guez-López,Agnieszka Woźniak,Mei‐Jun Zhu,(unknown),(unknown),Mark Mayeda,Jonathan A. Fletcher,Patrick Schöffski,John F. Lyons,Neil T. Thompson,Nicola G. Wallis	49
7	The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non‐small cell lung cancer 2011 ·Cancer Science ·Brent Graham,Jayne Curry,Tomoko Smyth,Lynsey Fazal,Ruth E. Feltell,(unknown),(unknown),Brian Williams,Matthias Reule,Hayley C. Angove,David M. Cross,John F. Lyons,Nicola G. Wallis,Neil T. Thompson	65
8	Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930 2010 ·Molecular Cancer Therapeutics ·Timothy A. Yap,Mike I. Walton,(unknown),Melanie Valenti,Alexis de Haven Brandon,Paul D. Eve,Ruth Ruddle,Simon P. Heaton,Alan T. Henley,Lisa Pickard,Gowri Vijayaraghavan,John Caldwell,Neil T. Thompson,Wynne Aherne,Florence I. Raynaud,Suzanne A. Eccles,Paul Workman,Ian Collins,Michelle D. Garrett	59
9	AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders 2010 ·British Journal of Haematology ·Mark A. Dawson,Jayne Curry,(unknown),Philip Beer,Brent Graham,John F. Lyons,Caroline J. Richardson,Mike Scott,Tomoko Smyth,Matthew Squires,Neil T. Thompson,Anthony R. Green,Nicola G. Wallis	41
10	Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines 2009 ·Molecular Cancer Therapeutics ·Matthew Squires,Ruth E. Feltell,Nicola G. Wallis,Edward J. Lewis,Donna-Michelle Smith,David M. Cross,John F. Lyons,Neil T. Thompson	134
11	Aurora B kinase inhibition in mitosis: Strategies for optimizing the use of Aurora kinase inhibitors such as AT9283 2009 ·Cell Cycle ·Jayne Curry,Hayley C. Angove,Lynsey Fazal,John F. Lyons,Matthias Reule,Neil T. Thompson,Nicola G. Wallis	41
12	Activity of the Multi-Targeted Kinase Inhibitor, AT9283 on Imatinib-Resistant CML Models. 2008 ·Blood ·Ruriko Tanaka,Matthew Squires,Shinya Kimura,Asumi Yokota,Kirsty Mallett,Tomoko Smyth,Neil T. Thompson,Rina Nagao,Takahiro Yamauchi,Takashi Ushiki,John F. Lyons,Taira Maekawa	6
13	AT13148, an orally bioavailable AKT kinase inhibitor with potent anti-tumor activity in both in vitro and in vivo models exhibiting AKT pathway deregulation. 2007 ·Molecular Cancer Therapeutics ·John F. Lyons,(unknown),Steven J. Woodhead,Ruth E. Feltell,Matthias Reule,(unknown),Lisa C. A. Seavers,(unknown),(unknown),Donna Smith,Lynsey Fazal,Paul Workman,Ian Collins,Michelle D. Garrett,Neil T. Thompson	2
14	Hsp90 inhibition by AT13387 modulates growth factor and cytokine stimulated cell signalling in multiple cell lines. 2007 ·Cancer Research ·Neil T. Thompson,John F. Lyons,(unknown),Rachel McMenamin,Sheetal Patel,(unknown),Jon Lewis,Lynsey Fazal,Andrew Woodhead,Brent Graham,Christopher W. Murray	2
15	CD4+CD45RA+ and CD4+CD45RO+ T cells differ in their TCR-associated signaling responses 1999 ·European Journal of Immunology ·Simon R. Hall,(unknown),Neil T. Thompson,Wendy C. Rowan	41
16	Phospholipase D1 localises to secretory granules and lysosomes and is plasma-membrane translocated on cellular stimulation 1998 ·Current Biology ·Fraser D. Brown,Nicola Thompson,Khalid M. Saqib,Joanna M. Clark,Dale Powner,Neil T. Thompson,Roberto Solari,Michael J.O. Wakelam	175
17	Phospholipase D: Regulation and Functional Significance 1993 ·Advances in pharmacology ·Neil T. Thompson,L.G. Garland,Robert W. Bonser	25
18	Receptor-coupled phospholipase D and its inhibition 1991 ·Trends in Pharmacological Sciences ·Neil T. Thompson,Robert W. Bonser,L.G. Garland	93
19	A quantitative investigation into the dependence of Ca²⁺ mobilisation on changes in inositol 1,4,5‐trisphosphate levels in the stimulated neutrophil 1991 ·British Journal of Pharmacology ·Neil T. Thompson,Robert W. Bonser,J.E. Tateson,Graham D. Spacey,Roger Randall,H. F. Hodson,L.G. Garland	19
20	Evidence that a second stereochemical centre in diacylglycerols defines interaction at the recognition site on protein kinase C 1988 ·FEBS Letters ·Robert W. Bonser,Neil T. Thompson,H. F. Hodson,(unknown),L.G. Garland	15

About Neil T. Thompson

Neil T. Thompson is a scholar working on Genetics, Cell Biology and Hematology, having authored 47 papers that have together received 1.6k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (5 papers), PI3K/AKT/mTOR signaling in cancer (5 papers) and Cancer-related Molecular Pathways (5 papers). The work is most often cited by research in Cell Biology (307 citations), Molecular Biology (956 citations) and Oncology (328 citations). Neil T. Thompson has collaborated with scholars based in United Kingdom, United States and Japan. Frequent co-authors include John F. Lyons, L.G. Garland, Robert W. Bonser, Michael C. Scrutton, Nicola G. Wallis, Michael Wadsworth, M. J. Jarvis, Marcus Richards, Khalid M. Saqib and Matthew Squires. Their work appears in journals such as Nature Communications, Blood and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact